Our team was forged through the shared experience of conceiving, inventing, and successfully advancing our own novel therapeutic programs in a startup environment—from initial scientific concept through some of the highest-risk stages of drug development pre clinical and clinical. That work went on to receive international recognition and support from the European Union and the WHO Global Task Force on Cholera Control (GTFCC) for its potential to deliver significant humanitarian impact.

Our core R&D, management, and regulatory team originally came together around a humanitarian mission: developing new therapies for serious gastrointestinal diseases where drug development had been limited by fundamental scientific barriers. Together, we designed and developed two first-in-class therapeutic approaches and advanced them from concept into human clinical development, including Phase II.

One of these programs, our novel first-in-class therapy for cholera and severe secretory diarrhea, ultimately led to the formation of HUNADIA, a multicontinental consortium built around our technology and bringing together partners across 10 countries to advance the program toward Phase III with support of EU and WHO.

Solving these difficult therapeutic problems required new technologies and unconventional approaches to gut-localized drug development.

That experience taught us how to tackle difficult targets and ultimately led to EL-924 and a growing pipeline targeting obesity, insulin resistance, inflammatory bowel disease, functional GI disorders, and other GI-driven diseases.

Our scientific foundation was shaped by work at leading academic institutions, including Yale and Vanderbilt, and further advanced through independent R&D and clinical development.

Elaphron was founded to translate this collective experience into a new generation of gut-directed therapies.